Molecular determinants underlying DS2 activity at δ -containing GABA_A receptors

Christina B. Falk-Petersen, Frederik Rostrup, Rebekka Löffler, Stine Buchleithner, Kasper Harpsøe, David E. Gloriam, Bente Frølund, and Petrine Wellendorph*

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences,
University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

*corresponding author

E-mail: pw@sund.ku.dk

Keywords

Extrasynaptic GABA_A receptor, allosteric modulator, binding site

Author Contributions

C.B.F-P., F.R., K.H., D.E.G., B.F., and P.W. designed the research. C.B.F-P., F.R., R.L., S.B., and K.H. conducted the experiments. F.R. and B.F. provided new reagents. C.B.F-P., F.R., R.L., S.B., K.H. and P.W. analyzed data, and C.B.F-P., K.H., and P.W. wrote the paper.

Competing interest statement

The authors declare no competing interests.

This PDF file includes:

Main Text

Figures 1 to 3

Tables 1 to 3

Abstract

Delta selective compound 2 (DS2) is one of the most widely used tools to study selective actions mediated by δ subunit-containing GABA_A receptors. DS2 was discovered over 10 years ago, but despite great efforts, the precise molecular site of action has remained elusive.

Using a combination of computational modeling, site-directed mutagenesis and cell-based pharmacological assays, we probed three potential binding sites for DS2 and analogs at $\alpha_4\beta_1\delta$ receptors: an $\alpha_4^{(+)}\delta^{(-)}$ interface site in the extracellular domain (ECD), equivalent to the diazepam binding site in $\alpha\beta\gamma_2$ receptors, and two sites in the transmembrane domain (TMD); one in the $\alpha_4^{(+)}\beta_1^{(-)}$ and one in the $\alpha_4^{(-)}\beta_1^{(+)}$ interface, with the $\alpha_4^{(-)}\beta_1^{(+)}$ site corresponding to the binding site for etomidate and a recently disclosed low-affinity binding site for diazepam. We show that mutations in the ECD site did not abrogate DS2 modulation. However, mutations in the TMD $\alpha_4^{(+)}\beta_1^{(-)}$ interface, either α_4 (S303L) of the $\alpha_4^{(+)}$ -side or β_1 (I289Q) of the $\beta_1^{(-)}$ -side, convincingly disrupted the positive allosteric modulation by DS2. This was consistently demonstrated both in an assay measuring membrane potential changes and by whole-cell patch-clamp electrophysiology and rationalized by docking studies. Importantly, general sensitivity to modulators was not compromised in the mutated receptors. This study sheds important light on the long-sought molecular recognition site for DS2, refutes the misconception that the selectivity of DS2 for δ -containing receptors is caused by a direct interaction with the δ -subunit, and instead points towards a functional selectivity of DS2 and its analogs via a surprisingly well-conserved binding pocket in the TMD.

Significance statement

δ -Containing GABA_A receptors represent potential drug targets for the treatment of several neurological conditions with aberrant tonic inhibition. Yet, no drugs are currently in clinical use. With the identification of the molecular determinants responsible for positive modulation by the known compound DS2, the ground is laid for design of ligands that selectively target δ -containing GABA_A receptor subtypes, for better understanding of tonic inhibition, and, ultimately, for rational development of novel drugs.

Introduction

Inhibition in the brain is primarily mediated by γ -aminobutyric acid (GABA) acting through GABA receptors, with the ionotropic GABA_A receptors (GABA_AR) being responsible for fast inhibition. Thus, GABA_ARs play an essential role in transmitting inhibitory signaling in the brain. Structurally speaking, GABA_ARs belong to the Cys-loop receptor family of pentameric receptor complexes and are composed from a repertoire of 19 different subunits in mammals, with the most commonly expressed in the CNS being α_{1-6} , β_{1-3} , γ_{1-3} and δ (1). The subunit stoichiometry of the archetypical GABA_A receptor is 2 α , 2 β and a third subunit most typically being either a γ or a δ -subunit, but other stoichiometries have also been reported (1). Studies on the subunit arrangement of the most abundantly expressed synaptic subtype, $\alpha_1\beta_2\gamma_2$, and a number of other γ -containing subtypes, show that the subunits are arranged as γ - β - α - β - α in a counterclockwise fashion around the central ion channel (2, 3). Although it is generally accepted that the δ -subunit in its cognate receptors simply replaces the γ -subunit with respect to arrangement (4), this is still not unequivocally established (5–8). Irrespectively, the orthosteric binding sites are located at the $\beta^{(+)}\alpha^{(-)}$ interfaces in the extracellular domain (ECD), and a number of allosteric binding sites have also been identified in the subunit interfaces in both the ECD and transmembrane domain (TMD) (9). These include for example the benzodiazepine site in the ECD $\alpha^{(+)}\gamma^{(-)}$ interface, responsible for mediating the anxiolytic and sleep-inducing effect of the benzodiazepines, including diazepam (Valium®), widely used in the clinic (10, 11).

The δ -containing GABA_ARs are located primarily at extrasynaptic sites where they mediate tonic (persistent) inhibition (12, 13), hence controlling neuronal excitability (14). Tonic inhibition is involved in various physiological responses and pathophysiological conditions (15) underlining δ -GABA_AR as valuable drug targets. THIP (gaboxadol), a δ -selective super agonist (16), was in a clinical phase III trial for treatment of primary insomnia, but failed (17) and have been in clinical trials (OV101) for the treatment of two rare disorders Fragile-X (trial number NCT03697161) (18) and Angelman syndrome (trial number NCT02996305) (19). Additionally, several neurological disorders such as stroke (20, 21) and epilepsy (22, 23), underline the continued interest in targeting these receptors. This also includes an emerging relevance for immunomodulation via actions on peripheral δ -containing receptors or equivalents (24, 25). However, compared to the synaptic γ -containing receptors, pronounced insight into the physiological and pathophysiological role of δ -containing receptors is still limited by the low number of potent and selective compounds.

In addition to THIP, another compound with selectivity for the δ -containing receptors is the positive allosteric modulator (PAM) delta selective compound 2 (DS2; 4-Chloro-*N*-[2-(2-thienyl)imidazo[1,2-*a*]pyridin-3-yl]benzamide) (26). DS2 has been used extensively as a tool compound to confirm the presence of δ -receptor-mediated tonic currents both in *in vitro* and *in vivo* studies (27–30). DS2 was identified in a screening campaign and reported as a δ -selective PAM at $\alpha_4\beta_3\delta$ GABA_ARs, showing no or limited effects at $\alpha_4\beta_3\gamma_2$ and $\alpha_1\beta_3\gamma_2$ receptors (26). This selectivity was confirmed in thalamic relay neurons, where only extrasynaptic tonic currents were enhanced (26). In 2013, Jensen *et al.* confirmed the reported selectivity for δ -containing receptors, using $\delta^{-/-}$ mice showing that this effect is clearly dependent on the δ -subunit (31). DS2 displays limited brain permeability (31) but was, nonetheless, shown to improve recovery after stroke in mice, plausibly by dampening peripheral immune activation (24). Recently, a methoxy analog of DS2, termed DS2OMe, was identified and confirmed to have a similar potency and subtype selectivity as DS2. Interestingly, the derived positron emission tomography (PET) tracer of DS2OMe, [¹¹C]DS2OMe, has been shown to have potential as a PET tracer for visualization of δ -containing receptors in brains of larger mammals such as pig (32).

In 2018, the first cryogenic electron microscopy (cryo-EM) structure of a human GABA_AR pentamer $\alpha_1\beta_2\gamma_2$ was published (33). Following this, the structure of the human $\alpha_1\beta_3\gamma_2$ receptor was solved in complex with diazepam, revealing both the known high-affinity diazepam binding site in the $\alpha^{(+)}\gamma^{(-)}$ interface in the extracellular domain (ECD), and a novel low affinity binding site located in the $\alpha^{(+)}\beta^{(-)}$ interface of the transmembrane domain (TMD) of the receptor (34). This low-affinity diazepam binding site is located in the same pocket as the binding site for the general anesthetics (e.g. etomidate) (35) which is also the proposed binding site for AA29504 (36). Additionally, similar sites are suggested to be present in all five inter-subunit interfaces in the TMD (37–39).

Based on the notion that binding pockets evolved through nature are often highly conserved, combined with the structural similarities between DS2 and benzodiazepine ligand zolpidem (40), we hypothesized that these diazepam binding pockets are similarly present in δ -containing subtypes and that either of them could represent the long-sought DS2 molecular recognition site for DS2.

We here report the identification of two residues, α_4 (S303) and β_1 (I289), within the predicted $\alpha_4^{(+)}\beta_1^{(-)}$ interface of the TMD in $\alpha_4\beta_1\delta$ receptors, that are necessary for DS2 modulation. This is supported by docking of DS2 and analogs into the identified binding pocket.

Material and Methods

Chemicals and materials

The compounds DS2; (4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridin-3-yl]benzamide), AA29504; ([2-amino-4-(2,4,6-trimethylbenzylamino)-phenyl]-carbamic acid ethyl ester), etomidate; ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester), picrotoxin and GABA were obtained from Tocris Bioscience (Bristol, UK). DS2OMe (4-Methoxy-N-[2-(thiopen-2-yl)imidazole[1,2-a]pyridine-3-yl]benbamide) was synthesized in-house as described previously (32). DMEM with GlutaMAX-I, FBS, penicillin-streptomycin, hygromycin B, trypsin-EDTA, DPBS and HBSS were purchased from Life Technologies (Paisley, UK). DMSO, HEPES, MgCl₂, CaCl₂, poly-D-lysine (PDL) and MgATP were purchased from Sigma-Aldrich (St. Louis, MO, USA). The FLIPR membrane potential Blue dye was purchased from Molecular Devices (Crawley, UK) and Polyfect transfection reagent from Qiagen (West Sussex, UK). Stocks of DS2 and DS2OMe were prepared at 1 mM and 10 mM concentrations in DMSO with final DMSO concentration <0.1%. Due to moderate solubility and 4x concentrations used in the FMP assay, the FMP buffer was preheated to 37 °C in a water bath before addition of compound and preparation of serial dilutions. Only stocks with final concentrations below 12 μM were used for further dilutions. Furthermore, higher concentrations were prepared separately.

Cells and transfections

A HEK-293 Flp-In cell line stably expressing the human δ-GABA_AR subunit (28) was used for transfection with human α- and β-subunits to express recombinant wildtype and mutant GABA_ARs and transfection ratios optimized as described (28). Cells were maintained in DMEM containing GlutaMAX-I, supplemented with 10% FBS and 1% penicillin-streptomycin and kept in an incubator at 37 °C and a humidity of 5% CO₂. 200 μL/ml hygromycin B was added to the media as positive selection. Transfection was performed using Polyfect (Qiagen) following the manufacturer's instructions except for using half the volume of transfection reagent for each transfection. α- and β-subunits were co-transfected in a 1:1 ratio for FMP experiments, and for patch-clamp experiments additionally co-transfected with GFP in a 0.5:1:1 ratio (0.8 μg:1.6 μg:1.6 μg in 6 cm culture dishes) in order to visualize transfected cells.

Plasmids and mutant constructs

The plasmids used for transfection to transiently express GABA_A receptors have been

described previously (28). The WT human α_4 and β_1 subunits were subcloned into the pUNIV vector (Addgene, Cambridge, MA, USA) and the human δ -subunit into the pcDNA5/FRT vector (Invitrogen, Paisley, UK) using the δ -construct described previously (28). Plasmids carrying single and double mutations were generated and sequence-verified by GenScript (Piscataway, NJ, USA). The numbering of the mutants refers to the sequences with the signal peptide included.

Generation of stable cell lines

Mutations introduced into the δ -subunit were established as stable HEK293 Flp-InTM cell lines (Invitrogen, Paisley, UK), generating a stable cell line for each mutant. The stable cell lines were generated using the pcDNA/FRT/V5-His TOPO TA Expression kit (Invitrogen) performed according to the manufacturer's protocol and as described previously (28), except for using 25 μ L Polyfect and 4 μ g DNA for transfection in a 10 cm culture dish.

FLIPR membrane potential (FMP) assay

The FLIPR membrane potential (FMP) assay was performed exactly as described previously (28). In brief, 48 hours before the assay, cells were transfected. 16-20 hours later, cells were plated into clear-bottomed PDL (poly-D-lysine)-coated black 96-well plates in a number of 50,000 cells/well, suspended in cell media, and placed in an incubator at 37 °C with a humidity of 5% CO₂ until performing the assay. 44-48 hours post-transfection, the media was removed, cells were washed in assay buffer (100 μ L/well) and incubated in 100 μ L/well 0.5 mg/mL FMP blue dye freshly dissolved in assay buffer (HBSS containing 20 mM HEPES adjusted to pH 7.4 and supplemented with 2 mM CaCl₂ and 0.5 mM MgCl₂) for 30 min shielded from light in an incubator at 37° C and a humidity of 5% CO₂. Ligand solutions were prepared in 4x assay buffer and added to a ligand plate, which was placed in the FLEXstation3 plate reader (Molecular Devices, Crawley, UK), preheated to 37° C for temperature equilibration for 10-15 min. After transferring the cell plate to the reader, the fluorescence was measured at baseline and after ligand addition by detecting emission at 560 nm caused by excitation at 530 nm.

FMP data analysis, exclusion criteria and statistics

Compound-induced signals were reported as changes in fluorescence units (Δ RFU), with the signal given as the difference between the average of the baseline signal (approx. 30 s recording) subtracted the peak response (or minimum response for decreases in baseline). All

raw traces were manually inspected for obvious artefacts after compound addition. For high concentrations of DS2 (1-20 μ M) we regularly observed negative RFU values below the buffer responses that in certain cases were excluded (see below). This phenomenon was independent of receptor subtype as it was observed for both δ -HEK and mock cells. The phenomenon was less pronounced for DS2OMe why this compound was preferred in some sub-studies. To circumvent this problem, we set up the following exclusion criteria: negative Δ RFU or decreased Δ RFU values for high concentration (>1 μ M) of DS2 and DS2OMe compared to the Δ RFU for a lower concentration in the same experiment (indicative of precipitation). Additionally, as a rule of thumb, the group size was to be at least $n=3$, or what was needed to obtain a SEM value < 0.2 . Additionally, curve fittings resulting in ambiguous EC_{50} values, and R^2 values lower than 0.80 were omitted from analyses.

Concentration-response curves were fitted using nonlinear regression, with the log-transformed concentration as x-values, using the four-parameter concentration-response equation:

$$\text{Response} = \text{bottom} + \frac{\text{top} - \text{bottom}}{1 + 10^{[(\log EC_{50} - x) \cdot n_H]}}$$

to determine the EC_{50} value and Hill slope. The ‘bottom’ and ‘top’ denotes the upper and lower plateau of the curve, respectively. The calculated EC_{50} values were log-transformed to obtain mean pEC_{50} values. Statistical analysis of mutated receptors was performed on the pEC_{50} values using the two-sided Welch’s t-test compared to WT, correcting for multiple comparison using the original FDR method of Benjamini and Hochberg with a discovery rate of 0.05. Both adjusted and un-adjusted P-values are reported. The data and statistical analysis were performed in GraphPad Prism (v. 8.4.3; GraphPad, San Diego, CA, USA).

Whole-cell patch-clamp electrophysiology

Whole-cell patch-clamp experiments were performed on δ -HEK cells transiently co-expressing WT or mutant α - and β -subunits and GFP as described previously (41). In short, the transfected cells were transferred to 35 mm petri dishes (100,000-200,000 cells) the day prior to performing the experiment. On the day of experiment, cell media was exchanged for ABSS (containing the following (in mM): NaCl 140, KCl 3.5, Na_2HPO_4 1.25, $MgSO_4$ 2, $CaCl_2$ 2, glucose 10, and HEPES 10; pH 7.35) at room temperature (20-24 $^{\circ}C$), before placing at the stage of an Axiovert 10 microscope (Zeiss, Germany). Viewing the cells at 200 $\times$ magnification and visualizing cells containing green fluorescent protein with UV light from an HBO 50 lamp

(Zeiss, Germany), the cells were approached with micropipettes of 1.2–3.3 M Ω resistance manufactured from 1.5 mm OD glass (World Precision Instruments, Sarasota, Florida, USA) on a microelectrode puller, model PP-830 (Narishige, Tokyo, Japan). The micropipettes contained an intracellular solution composed of the following (in mM): KCl 140, MgCl₂ 1, CaCl₂ 1, EGTA 10, MgATP 2, and HEPES 10; pH 7.3.

Recordings were made from cells in the whole-cell configuration using the standard patch-clamp technique in voltage mode and an EPC-9 amplifier (HEKA, Lambrecht, Germany). The clamping potential was -60 mv and series resistance was 80% compensated. Whole-cell currents were recorded using Pulse and PulseFit software (v.8.80, HEKA). Ligand solutions, prepared in ABSS, were applied using two VC3-8xP pressurized application systems feeding into a sixteen-barreled perfusion pipette (ALA Scientific Instruments Inc., Farmingdale, NY, USA) ending approximately 100 μ m from the recorded cell. PAMs were tested using co-application with a concentration of GABA corresponding to GABA EC₁₀₋₃₅ at the respective receptor subtype. Preapplication was not used for DS2 and DS2OMe, as results from preliminary experiments showed no difference in the size of the peak current with and without preapplication of the PAM. PAMs and GABA was co-applied for 10-30 s until the peak current was reached. Agonists was applied for 5 s. Between compound applications, compound-free ABSS was applied from one of the barrels in order to quickly remove the compounds from the cell and cells were allowed to recover for 1 min before the next ligand application.

Patch-clamp data analysis and statistics

All currents were normalized to the maximum GABA current and given as % I/I_{max}. All currents are reported as normalized mean currents with 95% confidence interval, determined based on currents from at least five different cells from at least two transfections. Datasets with GABA controls (0.1-0.5 μ M) deviating from GABA EC₁₀ to EC₃₅ were excluded from the analysis.

Statistical analysis was applied to test whether the PAMs potentiated the GABA control response using two-side Welch's t-test as for FMP data. Analysis of currents was performed using Pulse and Pulsefit (HEKA) and current traces were visualized using IgorPro (v. 6.2.2.2, Wavemetrics, Lake Oswego, OR, USA). Collected data and statistical analysis were performed using GraphPad Prism (v. 8.4.3).

Homology model for the extracellular domain binding site

The homology model of the ECD $\alpha_4^{(+)}\beta_1^{(-)}$ interface has been described previously (40). The model was used to identify residues for the mutational study based on the docking of DS2 into the model described previously (40).

Homology model for the transmembrane binding site

The homology model of the transmembrane part of the $\alpha_4\beta_1$ interface was constructed with Modeller 9.24 (42) using the $\alpha_1\beta_3$ interface from the $\alpha_1\beta_3\gamma_{2L}$ crystal structure (PDB code 6HUP (34)) as template. Model and template sequences of the TM helices and the connecting loops making up the subunit interface were obtained and aligned in UniProt (<http://www.uniprot.org/> (43)); sequence IDs α_4 P48169, β_1 P18505, α_1 P114867 and β_3 P28472. To adhere as much as possible to the very closely related template structure, the “very fast” keyword was utilized to output the initial model that is only subjected to a brief optimization, thus, retaining the copied coordinates for all conserved residue positions. This procedure was selected based on the high sequence similarities and assumed structural conservation combined with the fact that the binding site residues are optimized relative to the ligand in following computational steps.

Induced-fit docking of DS2 into the transmembrane $\alpha_4^{(+)}\beta_1^{(-)}$ site and in silico mutagenesis

The homology models were prepared for docking with the Protein Preparation Wizard (Schrödinger Release 2020-2, Schrödinger, LLC, New York, NY, 2020 (44)) using default settings. The chemical structure of DS2 was downloaded from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov> (45) CID: 979718)) and the analogs DS2OMe (32) and DS2OPh (40) were built from DS2 in MarvinSketch 20.15.0, ChemAxon (<http://www.chemaxon.com>). All three ligands were prepared for docking with default settings in LigPrep (Schrödinger Release 2020-2) and used for induced-fit docking in the model of the transmembrane $\alpha_4\beta_1$ interface with the Standard Protocol. The binding site center was defined by Ser303 and Ala324 from α_4 plus Pro253 and Ile289 from β_1 . The ligand length was set to ≤ 14 Å and XP precision was used in the re-docking step, while all other settings were default. The best-scoring docking poses according to the IFD score were selected for each compound as the most likely binding mode. *In silico* mutagenesis was performed with the built-in protein mutagenesis wizard in PyMOL (Molecular Graphics System, Version 2.0 Schrödinger, LLC.) and the backbone dependent rotamer library selecting the most probable rotamer with the fewest steric clashes with surrounding residues. For α_4 S303L and β_1 I289Q mutations the first (1 of 4, 47.4%) and second (2 of 16, 14.6%) most likely rotamers were selected, respectively.

Results and Discussion

To identify central residues for the activity of DS2 at δ -containing GABA_ARs, we systematically investigated three potential binding pockets: one in the ECD (the $\alpha_4^{(+)}\delta^{(-)}$ interface), and two in the TMD (the $\alpha_4^{(+)}\beta_1^{(-)}$ and the $\beta_1^{(+)}\alpha_4^{(-)}$ -interfaces). Although δ -containing TMD interfaces are present in the receptor complex we focused solely on the α - β interfaces due to the confirmed existence of binding sites at these interfaces (46–48), and our focus on benzodiazepine binding sites as potential binding sites for DS2 due to the structural resemblance between DS2 and zolpidem (40). Key interacting residues were identified using homology models and pharmacologically characterized in well-established HEK cell-based assays using the $\alpha_4\beta_1\delta$ receptor as a model receptor, that has been carefully characterized in our hands (27, 28, 41).

Investigation of the ECD $\alpha^{(+)}\delta^{(-)}$ interface as a potential site of action for DS2

First, using the homology model published in (40), we studied the pocket located in the C-loop of the $\alpha^{(+)}\delta^{(-)}$ interface in the ECD of $\alpha_4\beta_1\delta$ receptors (Fig. 1A). From our previous docking into the model, we identified three potential key residues on the $\alpha_4^{(+)}$ -side of the interface that could either interact directly with DS2 or were placed centrally within the binding pocket: α_4 (F133), α_4 (R135) and α_4 (G191) (Fig. 1A). Additionally, five residues on the complementary $\delta^{(-)}$ -interface were identified: δ (E71), δ (A73), δ (F90), δ (S155) and δ (H204). The selected residues were mutated with the principle of removing potential interactions (into alanine) and/or gradually decreasing the space in the binding pocket (into various amino acid residues), thus expecting a reduced modulation by DS2 compared to WT. This resulted in seven different α_4 -subunit mutants and five different δ -subunit mutants (Table S1+S2). Each of the mutated subunits were expressed in HEK cell lines to form $\alpha_4\beta_1\delta$ receptors and tested in the FMP assay, as single mutants. Whereas α_4 -mutants were simply co-transfected with WT β_1 into WT stable δ -HEK293 Flp-In cells, each of the δ -mutants were established as stable HEK293 Flp-In cell lines transfected with WT $\alpha_4\beta_1$ to transiently express $\alpha_4\beta_1\delta$. In general, extending the utility of this expression system from WT to mutated δ -containing receptors is highly reliable and suitable for controlling expression and reliably studying these in some instances, cumbersome receptor subtypes (49).

All seven α_4 -mutant receptors were found to express functionally active receptors, and to respond to GABA with 2-3 times the potency observed for WT (Fig. 1B,C, Fig. S1, Table S1).

The expression levels of $\alpha_4(\text{F133A/L})\beta_1\delta$ and $\alpha_4(\text{G191E})\beta_1\delta$ appeared lower as compared to WT, as the max ΔRFU values were consistently reduced in all experiments (Fig. 1B). To characterize the sensitivity to DS2, it was applied together with a GABA EC_{20} concentration, calculated for each mutant (Table 1, S2). Among the seven different α_4 -mutants, $\alpha_4(\text{F133A})\beta_1\delta$ and $\alpha_4(\text{G191E})\beta_1\delta$ showed no apparent or only small modulation by DS2, whereas the potency of DS2 at the other α_4 -subunit mutants was either unchanged ($\alpha_4(\text{F133L})\beta_1\delta$, $\alpha_4(\text{R135A})$ and $\alpha_4(\text{G191A/L})\beta_1\delta$) or slightly increased, ($\alpha_4(\text{R135H})\beta_1\delta$), compared to WT (Fig. 1D-F, Table 1+ Fig. S1, Table S2). Interestingly, only a single of the introduced mutations at $\alpha_4(\text{F133})$ and $\alpha_4(\text{G191})$ showed changed responses, which could not readily be explained.

As we and others have previously observed methodological limitations in the FMP assay (26, 28), we suspected that the apparent lack of modulation could be due to sensitivity limitations. Thus, to follow up, the two mutants $\alpha_4(\text{F133A})$ and $\alpha_4(\text{G191E})$ were tested using whole-cell patch clamp electrophysiology. At both mutated receptors, DS2 modulated the GABA EC_{20} -induced currents in a concentration-dependent manner similar to, or even more than, WT (Fig. 1G,H). An explanation for the discrepancy between the two assays could be the low expression of these specific mutant receptors which precludes the modulation to be picked up in the less sensitive FMP assay. Each of the five δ -subunit mutations were also tested in the FMP assay. These were all functional and displayed unchanged responsiveness to DS2 compared to WT (Fig. S2, Table S3,4).

Altogether, we conclude that the C-loop pocket in the ECD $\alpha_4^{(+)}\delta^{(-)}$ -interface is not the site responsible for the PAM effect of DS2. This is consistent with substituent and bio-isostere effects from a recent SAR study, focused on the ECD $\alpha_4^{(+)}\delta^{(-)}$ as a potential binding site (40).

Investigation of the TMD $\alpha_4^{(+)}\beta_1^{(-)}$ interface as the site of modulation by DS2

Instead, we looked into two pockets in the TMD $\alpha\beta$ -interfaces (specifically involving TM2), as potential recognition sites for DS2, which proved to be an advantageous avenue.

The first pocket is located in the $\beta^{(+)}\alpha^{(-)}$ interface in a site equivalent to the recently identified low-affinity binding site for diazepam (46). We hypothesized analogous binding circumstances for diazepam and DS2 in the TMD. Mutations in $\alpha_4\beta_1\delta$ TMD pockets were suggested based on the cryo-EM structure of the human GABA_AR $\alpha_1\beta_3\gamma_{2L}$ (PDB-code: 6HUP) in combination with a sequence alignment due to the high (>90%) local sequence identity of the subunits within the TMD region of interest.

The mutations, β_1 (S290F) on the $\beta_1^{(+)}$ side and α_4 (L302Y) on the $\alpha_4^{(-)}$ side were initially probed due to an apparent central positioning of the residues in the pocket and orientation towards diazepam in the cryo-EM structure (Fig. 2A). As a similar pocket is present at the reverse subunit interface, we also included the corresponding mutations in the $\alpha_4^{(+)}\beta_1^{(-)}$ interface, α_4 (S303L) on the $\alpha_4^{(+)}$ side and β_1 (I289Q) on the $\beta_1^{(-)}$ side. However, as this pocket appears noticeably smaller than the $\beta_1^{(+)}\alpha_4^{(-)}$ pocket, these were mutated into more flexible and less bulky residues. Additionally, to probe both proposed pockets simultaneously, we included the double mutant receptors α_4 (L302Y,S303L) $\beta_1\delta$ and $\alpha_4\beta_1$ (I289Q,S290F) δ . All of the introduced mutations were expected to revert hydrophilicity/hydrophobicity and introduce steric hindrance, and thus would be anticipated to decrease or altogether abolish the effect of DS2.

First, we show that all the single mutant receptors were GABA-responsive and thus functional in the FMP assay (Fig. 2B). The two β -mutants β_1 (S290F) and β_1 (I289Q), displayed 6.8 and 8.1 times increased GABA potencies, respectively, and the α_4 (S303L) $\beta_1\delta$ mutant 2.9 times increased potency compared to WT (Fig. 2C, Table S5). Since the receptors were functional, we continued with the studies.

In the modulation experiments, we switched to DS2OMe, an analog of DS2 (32) with the same pharmacological profile, because of both solubility issues with DS2 (described in the methods section) and the general sensitivity limitations observed in the FMP assay on the ECD mutants. First, we examined the modulation of GABA EC_{20} at mutations introduced in the $\beta^{(+)}\alpha^{(-)}$ interface, equal to the low affinity diazepam binding site in the γ -containing receptor (Fig. 2D). These mutations did not affect the modulation by DS2OMe as both the $\alpha_4\beta_1$ (S290F) δ and α_4 (L302Y) $\beta_1\delta$ mutant receptors had DS2OMe potencies similar to WT, although a small significant increase in efficacy for the α_4 (L302Y) $\beta_1\delta$ mutant compared to WT was observed (**P=0.0063, two-tailed Welch's t-test, response of 3 μ M DS2OMe) (Fig. 2D,F, Table 2). Altogether, we conclude that the $\beta^{(+)}\alpha^{(-)}$ interface site is not involved in the effect of DS2, and that the changed potency of GABA did not affect the modulation of the receptors by DS2OMe.

By contrast, when turning to the alternative $\alpha_4^{(+)}\beta_1^{(-)}$ interface, we observed significant decreases in responsiveness to modulation by DS2OMe. The α_4 (S303L) $\beta_1\delta$ receptor lacked responsiveness to modulation by DS2OMe, and the β -mutant receptor, $\alpha_4\beta_1$ (I289Q) δ had a 3.2 times reduction of the potency of DS2OMe compared to the WT receptor (Fig. 2E,F, Table 2).

Additionally, as expected from the individual mutations, the double mutant receptor α_4 (L302Y,S303L) $\beta_1\delta$ was not modulated by DS2OMe (Fig. S3, Table S6).

To verify the FMP results we performed whole-cell patch-clamp electrophysiology recordings. Convincingly, we found no or very limited DS2 modulation of the GABA currents in the α_4 (S303L) $\beta_1\delta$ and $\alpha_4\beta_1$ (I289Q) δ receptor (only 10 μ M modulated the $\alpha_4\beta_1$ (I289Q) δ receptor by significantly increasing the GABA control current to 54.8% of the GABA $I_{\max}$ (**P=0.0063, two-tailed Welch's t-test, adjusted, n=5-6)) (Fig. 2G,H). Further, we included the double mutant receptor α_4 (S303L) β_1 (I289Q) δ , which was even less modulated by 10 μ M DS2, amounting to 44% of the GABA $I_{\max}$ (*P=0.016, two-tailed Welch's t-test, adjusted, n=6-9) (Fig. S4, Table S3,6). DS2OMe showed no modulation of the GABA response in either $\alpha_4\beta_1$ (I289Q) δ or α_4 (S303L) $\beta_1\delta$ receptors, or the double mutant α_4 (S303L) β_1 (I289Q) δ receptor (Fig. S4,S5). Together, these results strongly advocate for the identified TMD $\alpha^{(+)}\beta^{(-)}$ interface site as the site responsible for the modulatory action of DS2.

Known GABA_AR PAMs show unchanged modulation at DS2-insensitive mutant receptors

To confirm that the mutant receptors with altered DS2 sensitivity were not overall compromised in their general PAM responsiveness, we tested etomidate (50) and AA29504 (36, 51) at both the WT and the single mutants α_4 (S303L) $\beta_1\delta$ and $\alpha_4\beta_1$ (I289Q) δ . In the FMP assay both compounds showed intact positive modulation of both mutants compared to WT. Potencies (EC₅₀) of etomidate were at WT $\alpha_4\beta_1\delta$ determined to 7.8 μ M, and for the α_4 (S303L) $\beta_1\delta$ and $\alpha_4\beta_1$ (I289Q) δ mutants to 6.2 μ M and 9.3 μ M, respectively (Fig. 2I,J, Table 3) (NS, two-tailed Welch's t-test, n=3-4). Additionally, AA29504 showed similar potentiation at the mutants and WT receptors (Fig. S6, Table S7), indicating that it does not mediate its effect through the same site as DS2, correlating with a proposed binding site for AA29504 in the TMD $\beta^{(+)}\alpha^{(-)}$ interface (36).

Induced-fit docking of DS2 and DS2OMe corroborates mutational results

Guided by the mutational data confirming the molecular recognition site mediating the effect of DS2 and DS2OMe in the transmembrane part of the $\alpha_4^{(+)}\beta_1^{(-)}$ subunit interface, we constructed a model of the modulator-receptor binding mode. Based on the structure of the desensitized $\alpha_1\beta_3\gamma_{2L}$ receptor bound to GABA and diazepam (34), we constructed a homology model of the $\alpha_4\beta_1$ subunit interface into which DS2 and DS2OMe were fitted using induced-

fit docking. Allowing residue side chains in the “empty” homology model to adapt to the modulators, we obtained very similar binding modes for the docked compounds (Fig. 3+S6). The core scaffold binds with the amide carbonyl of DS2 showing a potential hydrogen bond to the hydroxy group of Ser303 in α_4 . Using a backbone dependent rotamer library, we observe that the S303L mutation removes the hydrogen bond and sterically blocks the binding site – providing an explanation for the observed lack of potentiation on this mutant (Fig. 3B). Ile289 in β_1 lines 4-fluorophenyl of DS2, contributing to the binding through substantial van der Waal contacts, and the I289Q mutation has a steric clash with DS2 (Fig. 3B). As for the α_4 (S303L) mutant, these effects provide a possible explanation for the observed abolishment of potentiation at all but the highest concentration of DS2 and DS2OMe in our patch clamp experiments and the obtained binding mode thus concurs with the experimental results. Our previously published analogs of DS2 show that there should be room for much larger substituents than the methoxy of DS2OMe as well as a bromo atom in the 5-position on the imidazol[1,2-a]pyridine scaffold (40). Thus, we provide further proof-of-concept for the predicted binding site by docking the recently published analog, DS2OPh (40). This confirmed that the OPh substituent can fit the binding site in the homology model with only a minor shift in the binding mode (Fig. S6).

From our experiments using systematic structural iterations and experimental validation of known and proposed binding sites, we present the elusive DS2 interaction site encompassing α_4 S303 and β_1 I289 residues in the $\alpha_4^{(+)}\beta_1^{(-)}$ interface. The proposed binding site for DS2 is distinct and novel, yet similar in nature to the low-affinity diazepam binding site (46) and the general anesthetics binding site located in the alternative interface. Indeed, it has been reported that pockets exist in all the TMD inter-subunit interfaces (37, 38), and that several known allosteric modulators can bind in these pockets (9). From our data it is deduced that the δ -subunit is not directly involved in the modulation by DS2, questioning what determines the δ -selective profile of the compounds. It is plausible that this is a matter of functional selectivity, similar to that observed for the super agonist THIP, in which case binding in a highly conserved α - β interface gives rise to 10-times higher potency at the δ -containing receptors compared to both γ -containing and binary $\alpha\beta$ receptors with (16, 28, 52). Finally, having a homology model of the DS2 binding site, the next step is to use this for structure-based drug design of DS2-related analogs or a radiolabeled analog for further validation of the binding site.

Novel δ -selective analogs will aid to improve our understanding of the physiological and pathophysiological role of δ -containing receptors, and may, potentially, serve as leads for

future rational drug development to treat the vast majority of neurological disorders with dysregulated tonic inhibition and/or target conditions involving δ -containing GABA_A receptors in the periphery.

Acknowledgements

We would like to thank Dr. Uffe Kristiansen for intellectual input and scientific guidance with the patch-clamp electrophysiology studies, and Durita Poulsen for help with performing DNA preps. This work was financially supported by the Lundbeck Foundation (grant R230-2016-2562 to C.B.F-P. and R277-2018-260 to P.W.), and the Drug Research Academy (C.B.F-P.). F.R. was financially supported by a 2018 Lundbeck Foundation pre-graduate scholar stipend in Pharmaceutical Neuroscience.

References

1. R. W. Olsen, W. Sieghart, GABA_A receptors: subtypes provide diversity of function and pharmacology. *Neuropharmacology* **56**, 141–148 (2009).
2. V. Tretter, N. Ehya, K. Fuchs, W. Sieghart, Stoichiometry and assembly of a recombinant GABA_A receptor subtype. *J. Neurosci.* **17**, 2728–2737 (1997).
3. S. W. Baumann, R. Baur, E. Sigel, Forced subunit assembly in $\alpha_1\beta_2\gamma_2$ GABA_A receptors: insight into the absolute arrangement. *J. Biol. Chem.* **277**, 46020–46025 (2002).
4. N. Barrera, P. Herbert, Atomic force microscopy reveals the stoichiometry and subunit arrangement of $\alpha_4\beta_3\delta$ GABA_A receptor. *Mol. Pharmacol.* **73**, 960–967 (2008).
5. B. Patel, M. Mortensen, T. G. Smart, Stoichiometry of δ subunit containing GABA_A receptors. *Br. J. Pharmacol.* **171**, 985–994 (2014).
6. K. R. Wagoner, C. Czajkowski, Stoichiometry of expressed $\alpha_4\beta_2\delta$ γ -aminobutyric acid type A receptors depends on the ratio of subunit cDNA transfected. *J. Biol. Chem.* **285**, 14187–14194 (2010).
7. R. Baur, K. H. Kaur, E. Sigel, Structure of $\alpha_6\beta_3\delta$ GABA_A receptors and their lack of ethanol sensitivity. *J. Neurochem.* **111**, 1172–1181 (2009).
8. K. H. Kaur, R. Baur, E. Sigel, Unanticipated structural and functional properties of δ -subunit-containing GABA_A receptors. *J. Biol. Chem.* **284**, 7889–7896 (2009).
9. R. W. Olsen, GABA_A receptor: positive and negative allosteric modulators. *Neuropharmacology* **136**, 10–22 (2018).
10. E. Sigel, M. E. Steinmann, Structure, function, and modulation of GABA_A receptors. *J. Biol. Chem.* **287**, 40224–40231 (2012).
11. X. Simeone, *et al.*, Defined concatenated $\alpha_6\alpha_1\beta_3\gamma_2$ GABA_A receptor constructs reveal dual action of pyrazoloquinolinone allosteric modulators. *Bioorganic Med. Chem.* **27**, 3167–3178 (2019).
12. M. Farrant, Z. Nusser, Variations on an inhibitory theme: phasic and tonic activation of GABA_A receptors. *Nat. Rev. Neurosci.* **6**, 215–229 (2005).
13. I. Mody, Distinguishing between GABA_A receptors responsible for tonic and phasic conductances. *Neurochem. Res.* **26**, 907–913 (2001).
14. D. Belelli, *et al.*, Extrasynaptic GABA_A receptors: form, pharmacology, and function. *J. Neurosci.* **29**, 12757–63 (2009).
15. V. Lee, J. Maguire, The impact of tonic GABA_A receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. *Front. Neural Circuits* **8**,

- 3 (2014).
16. S. í Stórustovu, B. Ebert, Pharmacological characterization of agonists at δ -containing GABA_A receptors: functional selectivity for extrasynaptic receptors is dependent on the absence of γ_2 . *J. Pharmacol. Exp. Ther.* **316**, 1351–1359 (2006).
17. K. A. Wafford, B. Ebert, Gaboxadol - a new awakening in sleep. *Curr. Opin. Pharmacol.* **6**, 30–36 (2006).
18. P. Cogram, *et al.*, Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile X syndrome. *Front. Behav. Neurosci.* **13**, 141 (2019).
19. K. Egawa, *et al.*, Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of angelman syndrome. *Sci. Transl. Med.* **4**, 163ra157 (2012).
20. S. S. Smith, $\alpha_4\beta\delta$ GABA_A receptors and tonic inhibitory current during adolescence: effects on mood and synaptic plasticity. *Front. Neural Circuits* **7**, 135 (2013).
21. S. G. Brickley, I. Mody, Extrasynaptic GABA_A receptors: their function in the CNS and implications for disease. *Neuron* **73**, 23–34 (2012).
22. A. N. Clarkson, B. S. Huang, S. E. MacIsaac, I. Mody, S. T. Carmichael, Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. *Nature* **468**, 305–309 (2010).
23. M. E. K. Lie, *et al.*, GAT3 selective substrate L-isoserine upregulates GAT3 expression and increases functional recovery after a focal ischemic stroke in mice. *J. Cereb. Blood Flow Metab.* **39**, 74–88 (2019).
24. S. Neumann, *et al.*, The delta-subunit selective GABA_A receptor modulator, DS2, improves stroke recovery via an anti-inflammatory mechanism. *Front. Neurosci.* **13**, 1133 (2019).
25. G. T. Yocum, *et al.*, GABA_A receptor α_4 -subunit knockout enhances lung inflammation and airway reactivity in a murine asthma model. *Am. J. Physiol. Cell. Mol. Physiol.* **313**, L406–L415 (2017).
26. K. A. Wafford, *et al.*, Novel compounds selectively enhance δ subunit containing GABA_A receptors and increase tonic currents in thalamus. *Neuropharmacology* **56**, 182–189 (2009).
27. N. O. Dalby, *et al.*, Silencing of spontaneous activity at $\alpha_4\beta_{1/3}\delta$ GABA_A receptors in hippocampal granule cells reveals different ligand pharmacology. *Br. J. Pharmacol.* **177**, 3975–3990 (2020).
28. C. B. Falk-Petersen, *et al.*, Development of a robust mammalian cell-based assay for

- studying recombinant $\alpha_4\beta_1\delta$ GABA_A receptor subtypes. *Basic Clin. Pharmacol. Toxicol.* **121**, 119–129 (2017).
29. N. Zhang, *et al.*, Decreased surface expression of the δ subunit of the GABA_A receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome. *Exp. Neurol.* **297**, 168–178 (2017).
 30. N. Wongsamitkul, R. Baur, E. Sigel, Toward understanding functional properties and subunit arrangement of $\alpha_4\beta_2\delta$ γ -aminobutyric Acid, Type A (GABA_A) receptors. *J. Biol. Chem.* **291**, 18474–18483 (2016).
 31. M. L. Jensen, *et al.*, A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA_A receptors. *Br. J. Pharmacol.* **168**, 1118–1132 (2013).
 32. E. T. L'Estrade, *et al.*, Synthesis and pharmacological evaluation of [¹¹C]4-methoxy-N-[2-(thiophen-2-yl)imidazo[1,2-*a*]pyridin-3-yl]benzamide as a brain penetrant PET ligand selective for the δ -subunit-containing γ -aminobutyric acid type A receptors. *ACS Omega* **4**, 8846–8851 (2019).
 33. S. Zhu, *et al.*, Structure of a human synaptic GABA_A receptor. *Nature* **559**, 67–88 (2018).
 34. S. Masiulis, *et al.*, GABA_A receptor signalling mechanisms revealed by structural pharmacology. *Nature* **565**, 454–459 (2019).
 35. G. D. Li, *et al.*, Identification of a GABA_A receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. *J. Neurosci.* **26**, 11599–11605 (2006).
 36. E. R. Olander, N. Madjroh, L. Bunch, P. C. Söderhielm, A. A. Jensen, Delineation of the functional properties and the mechanism of action of AA29504, an allosteric agonist and positive allosteric modulator of GABA_A receptors. *Biochem. Pharmacol.* **150**, 305–319 (2018).
 37. S. A. Forman, K. W. Miller, Mapping general anesthetic sites in heteromeric γ -aminobutyric acid type A receptors reveals a potential for targeting receptor subtypes. *Anesth. Analg.* **123**, 1263–1273 (2016).
 38. M. T. Iorio, *et al.*, GABA_A receptor ligands often interact with binding sites in the transmembrane domain and in the extracellular domain – can the promiscuity code be cracked? *Int. J. Mol. Sci.* **21**, 334 (2020).
 39. W. Sieghart, J. Ramerstorfer, I. Sarto-Jackson, Z. Varagic, M. Ernst, A novel GABA_A receptor pharmacology: drugs interacting with the $\alpha^+\beta^-$ interface. *Br. J. Pharmacol.*

- 166**, 476–485 (2012).
40. B. Frølund, *et al.*, Structural determinants for the mode of action of the imidazopyridine DS2 at δ -containing γ -aminobutyric acid type A (GABA_A) receptors (2020) <https://doi.org/10.26434/chemrxiv.13395416.v1>.
41. C. B. Falk-petersen, *et al.*, Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA_A receptors. *Sci. Rep.* **10** (2020).
42. B. Webb, A. Sali, Comparative protein structure modeling using MODELLER. *Curr. Protoc. Bioinforma.* **54**, 5.6.1-5.6.37 (2016).
43. T. U. Consortium, UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47**, D506–D515 (2018).
44. G. M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J. Comput. Aided. Mol. Des.* **27**, 221–234 (2013).
45. S. Kim, *et al.*, PubChem 2019 update: improved access to chemical data. *Nucleic Acids Res.* **47**, D1102–D1109 (2018).
46. D. Lavery, *et al.*, Cryo-EM structure of the human $\alpha 1\beta 3\gamma 2$ GABA_A receptor in a lipid bilayer. *Nature* **565**, 516–520 (2019).
47. M. Ernst, S. Bruckner, S. Boresch, W. Sieghart, Comparative models of GABA_A receptor extracellular and transmembrane domains: important insights in pharmacology and function. *Mol. Pharmacol.* **68**, 1291–1300 (2005).
48. R. Puthenkalam, *et al.*, Structural studies of GABA_A receptor binding sites: which experimental structure tells us what? *Front. Mol. Neurosci.* **9**, 44 (2016).
49. N. Karim, *et al.*, Low nanomolar GABA effects at extrasynaptic $\alpha 4\beta 1/3\delta$ GABA_A receptor subtypes indicate a different binding mode for GABA at these receptors. *Biochem. Pharmacol.* **84**, 549–557 (2012).
50. C. Hill-Venning, D. Belelli, J. A. Peters, J. J. Lambert, Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. *Br. J. Pharmacol.* **120**, 749–756 (1997).
51. K. Hoestgaard-Jensen, *et al.*, Pharmacological characterization of a novel positive modulator at $\alpha 4\beta 3\delta$ -containing extrasynaptic GABA_A receptors. *Neuropharmacology* **58**, 702–711 (2010).
52. M. Mortensen, B. Ebert, K. Wafford, T. G. Smart, Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABA_A receptors. *J. Physiol.* **588**, 1251–1268 (2010).

Figures and Tables

Figure 2 Identification of the TMD $\alpha_4(+) \beta_1(-)$ site mediating modulation by DS2.

A Model of the $\alpha_4\beta_1\delta$ receptor with the TMD $\beta_1(+) \alpha_4(-)$ and $\alpha_4(+) \beta_1(-)$ interface mutants highlighted in the zoom-in (build on the cryo-EM structure of the $\alpha_1\beta_3\gamma_2$ receptor (PDB code: 6HUP)). **B** Single representative GABA concentration-response curves from WT $\alpha_4\beta_1\delta$ and TMD $\alpha\beta$ interface mutants (means $\pm$ SD, technical triplicates), and **C** bar diagram showing pooled pEC_{50} values (means with 95% CI (n=4-11)). Modulation of GABA EC_{20} by DS2OMe at **D** the $\beta_1(+) \alpha_4(-)$ and **E** the $\alpha_4(+) \beta_1(-)$ interface mutants. Data are representative curves from a single experiment with means $\pm$ SD of data normalized to GABA $_{max}$. **F** Bar diagram showing pooled pEC_{50} values (means with 95% CI (n= 4-7)). **G** Single cell current traces from DS2 modulation of GABA EC_{20} at WT and $\alpha_4(+) \beta_1(-)$ interface mutants. **H** Bar diagram summarizing the DS2 modulation of $\alpha_4(+) \beta_1(-)$ interface mutants in whole-cell patch-clamp electrophysiology. Currents are normalized to the GABA $_{max}$ current and are given as mean % I/I_{max} with 95% CI (n= 5-11). **I** Single representative concentration-response curves of the modulation of GABA EC_{20} by etomidate at the $\alpha_4(+) \beta_1(-)$ interface mutants, and **J** pooled pEC_{50} values (means with 95% CI with symbols representing values from independent experiments, (n = 4-5)). For C,F,H,J: Statistical analysis was performed using two-sided Welch's t-test compared to WT (C,F,J) or control current (H) and adjusted for multiple testing using the Original FDR method of Benjamini and Hochberg with a discovery rate of 0.05. Statistical significance * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$.

Figure 3 Binding model of DS2 in the TMD $\alpha_4^{(+)}\beta_1^{(-)}$ subunit interface.

Visualization of DS2 (sticks and grey carbon atoms) in the TMD interface between the α_4 (blue cartoon and carbon atoms) and β_1 (red cartoon and carbon atoms) GABA_A subunits, showing: **A** Residues with side chain atoms within 5 Å of DS2 are shown as lines highlighting the two important residues, α_4 S303 and β_1 I289, as sticks. The binding cavity is depicted as the vdW surface (grey and transparent) of the same residues and hydrogen bonds between DS2 and the receptor represented as yellow dotted lines. **B** *In silico* representation of the α_4 S303L and β_1 I289Q mutations (inserted residues as sticks with yellow carbon atoms) showing predicted steric clashes with DS2 as red disks explaining the hampered/abolished positive modulation of DS with these mutations. Figure prepared with the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.

Table 1. Potencies of DS2 at WT and ECD α_4 -mutant receptors determined in the FMP assay.

Receptor	DS2 (PAM)		95% CI	difference pEC ₅₀ [95% CI]	P-value	Adjusted p-value	EC ₂₀ (μ M)
	EC ₅₀ (μ M)	pEC ₅₀ ±SEM, n					
WT	0.97	(6.01 ± 0.076, 4)	5.77;6.25	-	-	-	0.06
α_4 (F133A) $\beta_1\delta$	- ^a	n=5	-	-	-	-	0.12
α_4 (F133L) $\beta_1\delta$	1.29	(5.89 ± 0.153, 3)	5.24;6.54	-0.12 [-0.65;0.42]	0.53	0.7857	0.12
α_4 (R135A) $\beta_1\delta$	1.41	(5.85 ± 0.031, 4)	5.76;5.95	-0.15 [-0.38;0.075]	0.14	0.4500	0.06
α_4 (G191A) $\beta_1\delta$	2.04	(5.69 ± 0.111, 4)	5.77;6.25	-0.32 [-0.66;0.02]	0.061	0.3050	0.12
α_4 (G191E) $\beta_1\delta$	- ^a	n = 5	-	-	-	-	0.06

^a not able to fit, but a small potentiation seen for concentrations higher than 1 μ M. EC₂₀; calculated GABA concentration coapplied with the PAM. Statistical analysis; two-tailed Welch's t-test compared to WT, adjusted for multiple comparison using the original FDR (Benjamini and Hochberg) method with discovery rate of 0.05.

Table 2. Potencies of DS2 at TMD mutant receptors determined in the FMP assay

Receptor	DS2OMe (PAM) (EC ₅₀ (μM), pEC ₅₀ ± SEM, n)		95% CI	Difference pEC ₅₀ [95% CI]	P-value	Adjusted EC ₂₀ P-value (μM)
WT	0.50	(6.30 ± 0.13, 5)	5.9;6.7	-	-	-
α ₄ (L302Y)β ₁ δ	0.35	(6.46 ± 0.061, 5)	6.3;6.6	0.17 [-0.19;0.52]	0.29	0.310
α ₄ (S303L)β ₁ δ	-	n = 3 ^a	-	-	-	-
α ₄ β ₁ (I289Q)δ	1.58	(5.80 ± 0.083, 7)	5.6;6.0	-0.49 [-0.85;-0.12]	0.015	0.045*
α ₄ β ₁ (S290F)δ	0.35	(6.46 ± 0.065, 4)	6.3;6.7	0.16 [-0.20;0.52]	0.31	0.310

^a no apparent potentiation (concentration range from 0.01 μM to 10 μM DS2OMe). EC₂₀; calculated GABA concentration co-applied with the PAM. Statistical analysis; Two-tailed Welch's t-test compared to WT adjusted for multiple comparison using the original FDR method of Benjamini and Hochberg with a discovery rate of 0.05. Significance level; *P<0.05.

Table 3. Potency of etomidate at $\alpha_4^{(+)}\beta_1^{(-)}$ TMD mutants determined in the FMP assay

Receptor	Etomidate (PAM)		95% CI	Difference pEC ₅₀ [95% CI]	P-value Adjusted		EC ₂₀ (μM)
	(EC ₅₀ (μM), pEC ₅₀ ± SEM, n)				P-value		
WT	7.8	(5.11± 0.055, 5)	5.1;7.4	-	-	-	0.06
α ₄ (S303L)β ₁ δ	6.2	(5.21 ± 0.14, 4)	6.0;7.2	-0.10 [-1.3;0.60]	0.36	0.66	0.02
α ₄ β ₁ (I289Q)δ	9.3	(5.03 ± 0.12, 5)	6.1;6.2	-0.07 [-1.42;1.31]	0.66	0.66	0.007

EC₂₀; calculated GABA concentration coapplied with the PAM. Statistical analysis; two-tailed Welch's t-test compared to WT and adjusted for multiple testing using the original FDR method of Benjamini and Hochberg with a discovery rate of 0.05.